Resolution therapeutics reports positive four-year MATCH trial data in liver cirrhosis
Resolution Therapeutics has highlighted positive four-year follow-up data from the MATCH trial evaluating macrophage cell therapy (RMT) in patients with liver cirrhosis. The data, generated by researchers at the University of Edinburgh, demonstrated the long-term safety and durability of the approach, with treated patients showing encouraging survival outcomes and reduced liver-related complications over the follow-up period.
The company is currently running its Phase 1/2 EMERALD trial of RTX001, an engineered regenerative macrophage therapy augmented with IL-10 and MMP9 to deliver stronger anti-inflammatory and anti-fibrotic activity than its predecessor. Interim results from EMERALD are expected later this year. For a disease area that has historically struggled to move beyond transplantation, long-term transplant-free survival data at this scale is meaningful clinical validation.
Read more via PharmaTimes
UCLA opens center for Advanced Biotherapies to expand development and delivery of cell and gene therapies
UCLA has opened the Center for Advanced Biotherapies (CAB), a new 14,000-square-foot FDA-compliant manufacturing facility built inside the UCLA Center for Health Sciences. The facility nearly doubles the university's capacity to manufacture personalised treatments and can produce up to 150 cell and gene therapy products per year. It was funded in part by a $7.3 million NIH grant and $2 million from the California Institute for Regenerative Medicine.
According to UCLA, the facility will support both investigator-led and industry-sponsored clinical trials while strengthening access to advanced biotherapy treatments for patients across the region. The expansion reflects the wider industry trend of academic medical centres investing heavily in CGT infrastructure to support increasing clinical demand and manufacturing complexity.
Read more via UCLA Newsroom and UCLA Health
Eli Lilly reports early results for gene-editing cholesterol therapy
Eli Lilly has reported positive early-stage clinical data for its investigational gene-editing therapy targeting high cholesterol, marking another step forward for in vivo CRISPR-based cardiovascular treatments.
The therapy, developed following Lilly’s acquisition of Verve Therapeutics, is designed to permanently reduce LDL cholesterol levels by editing the PCSK9 gene in the liver. Early clinical findings demonstrated reductions in LDL cholesterol broadly comparable to currently approved PCSK9 inhibitor therapies, while maintaining a favourable early safety profile.
The company is now preparing to advance the programme into Phase II development. The update reflects continued momentum within the gene-editing field as developers increasingly expand beyond rare disease applications into larger chronic disease markets such as cardiovascular disease.
Read more via BioPharma Dive and Fierce Biotech
)